ReviewInternational journal of clinical and experimental medicine2015
Leptin and its receptor in hematologic malignancies.
Review in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 25 citations in OpenAlex.
- Obesity as a risk factor for acute lymphoblastic leukemia in individuals younger than 20 years across 204 countries and territories from 1990 to 2021: a benchmarking global analysis.Annals of medicine and surgery (2012) · 2026Article
- Benign non-immune cells in tumor microenvironment.Frontiers in immunology · 2025Review
- Relationship between adipocytes and hematological tumors in the bone marrow microenvironment: a literature review.Translational cancer research · 2024Review
- Differential co-expression network analysis elucidated genes associated with sensitivity to farnesyltransferase inhibitor and prognosis of acute myeloid leukemia.Cancer medicine · 2023Article
- The Head-to-Toe Hormone: Leptin as an Extensive Modulator of Physiologic Systems.International journal of molecular sciences · 2022Review
- Article
- The Impact of Obesity on the Outcomes of Adult Patients with Acute Lymphoblastic Leukemia - A Single Center Retrospective Study.Blood and lymphatic cancer : targets and therapy · 2021Article
- Role of bone marrow adipocytes in leukemia and chemotherapy challenges.Cellular and molecular life sciences : CMLS · 2019Review
- Bone Marrow Adipocytes: The Enigmatic Components of the Hematopoietic Stem Cell Niche.Journal of clinical medicine · 2019Review
- Leptin and Immunological Profile in Obesity and Its Associated Diseases in Dogs.International journal of molecular sciences · 2019Review
- Vemurafenib Treatment of Pleomorphic Xanthoastrocytoma in a Child With Down Syndrome.Frontiers in oncology · 2019Article
- Body mass index throughout adulthood, physical activity, and risk of multiple myeloma: a prospective analysis in three large cohorts.British journal of cancer · 2018Observational
- Down Syndrome, Obesity, Alzheimer's Disease, and Cancer: A Brief Review and Hypothesis.Brain sciences · 2018Review
- The potential role of leptin in tumor invasion and metastasis.Cytokine & growth factor reviews · 2017Review
- Pro-inflammatory State in Monoclonal Gammopathy of Undetermined Significance and in Multiple Myeloma Is Characterized by Low Sialylation of Pathogen-Specific and Other Monoclonal Immunoglobulins.Frontiers in immunology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leptin is an adipocyte-derived cytokine coded by the obese gene, not only regulates metabolism, but also participates in hematopoiesis. Aberrant leptin levels in patients with hematologic malignancies were observed and associates with clinical characters, such as body mass index (BMI), gender, blast cell percentage. Leptin concentrations alter while diseases progress or remission. Leptin receptor is expressed in hematopoietic CD34+ stem cells, erythrocytes, lymphocytes, blast cells and samples in leukemia and lymphoma patients. The adipokine stimulates cell proliferation, cytokine secretion and protects malignant cells from apoptosis through Janus kinase-signal transducer and activator of transcription (JAK-STAT), mitogen-activated protein kinase and extracellular signal activated kinase 1/2 (MAPK/ERK1/2), or 3 kinase (PI3K) signaling pathways. These findings indicate leptin signaling possibility take part in occurrence, progression and prognosis of hematologic malignancies. This article reviews leptin/leptin receptor expression and the correlations with clinical characters, treatment and prognosis in myeloid and lymphoid neoplasms.
Indexed as
Identifiers
26884894PMC4723739W2281555552What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.